Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STSA-1301
- Development stage
- Phase 2
- Lead developer
- Staidson Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
STSA-1301 is a recombinant anti-human FcRn (neonatal Fc receptor) humanized IgG4 monoclonal antibody developed for the treatment of autoimmune diseases mediated by pathogenic IgG autoantibodies, such as idiopathic thrombocytopenic purpura (ITP). By specifically binding to the neonatal Fc receptor (FcRn), it blocks the recycling of IgG antibodies, leading to their accelerated degradation. This mechanism selectively reduces circulating pathogenic IgG without affecting other immunoglobulin classes like IgM or IgA. The drug is administered subcutaneously and is currently in clinical development with trials conducted primarily in China[1][2][3][5].
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on STSA-1301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STSA-1301.